Boston, Massachusetts and Paris (ots/PRNewswire) - - KIKA Medical Will Provide Global EDC Services for One of the Largest Drug-Eluting Stent Registries in the Cardiovascular Field KIKA Medical, a provider of advanced web-based solutions for Clinical Studies, announces today that it has been selected to provide EDC services for one of the largest drug-eluting stent post-marketing registries in the ...
Vienna, Austria (ots/PRNewswire) - sanofi pasteur, [NYSE: SNY] the vaccines business of the sanofi-aventis Group, today announced that its H5N1 pre-pandemic vaccine induces antibodies that neutralize additional H5N1 circulating virus not included in the original vaccine formulation. These data, presented at the 2nd International Conference on Influenza Vaccines ...
Fukuoka, Japan (ots/PRNewswire) - - Therapy May Benefit Hypertensive Patients With Additional Risk Factors in Populations Across Asia and Latin America Single-pill amlodipine besylate/atorvastatin calcium (Caduet(R)) may reduce the 10-year risk of having a cardiovascular (CV) event - as determined by the ...
New York (ots/PRNewswire) - Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal the ruling, but the patent will remain ...
Bristol-Myers Squibb Medical Imaging
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
Zurich (ots) - Prionics, the world leader in BSE and prion testing, has been recognized for its contribution to animal health and food safety. After being awarded with the European Biotech Award 2004, the nomination for the Animal Pharm Industry Awards honors the achievements of the Swiss biotech company in ...
Basel, Switzerland (ots/PRNewswire) - - FDA Grants Fast Track Status to R1626 Roche announced today the start of the first phase II development study to evaluate R1626, their promising new polymerase inhibitor, for the treatment of hepatitis C. The investigational drug has also been granted Fast Track ...
Bristol-Myers Squibb Medical Imaging
Journalists and other readers should disregard the news release "Bristol-Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY(TM) (perflutren lipid microsphere)" NYSE:BMY, issued earlier today. The release was issued prematurely by PR Newswire. ots Originaltext: Bristol-Myers Squibb Medical ...
Bristol-Myers Squibb Medical Imaging
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) reports final safety and efficacy data subsequent to 60 weeks of continuous treatment with ISA247. All safety and efficacy endpoints were met. Patients completing the 24 week Canadian Phase III SPIRIT trial were given the opportunity to continue ISA247 therapy at a 0.3 mg/kg twice daily oral dose ...
New York (ots/PRNewswire) - - Prototype Research Kits Approach Commercialization Phase and Target the Growing Field of Genomic-Based Molecular Diagnostics Xenomics, Inc. (OTC Bulletin Board: XNOM; FWB:XE7), the source of next-generation medical DNA diagnostic tests, today announced that it has developed a new method for the isolation of low molecular ...
Basel (ots/PRNewswire) - - Results Unveiled at ICAAC Show That Over 90% of Treatment-Experienced Patients Achieve Treatment Goal of Undetectable Viral Load Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON(R) (enfuvirtide) ...
Madrid (ots/PRNewswire) - PharmaMar today announced the successful planned review by the Independent Data Monitoring Committee (IDMC) of the YONDELIS(R) (trabectedin) Phase III pivotal clinical trial in ovarian cancer, known as OVA-301. The IDMC recommended that the present study should continue without ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received a No Objection Letter from Health Canada to conduct a pivotal Phase III European /Canadian clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Company ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company has been issued European Patent No. EP0991660 for its lead immunosuppressive drug, ISA247. The patent entitled "DEUTERATED AND UNDEUTERATED CYCLOSPORINE ANALOGS AND THEIR USE AS IMMUNOMODULATING AGENTS" is the ninth patent to be issued internationally in this patent family. ...
Macclesfield, England (ots/PRNewswire) - - For International Journalists - Not for US Media New data, presented for the first time today, show that a combination of ARIMIDEX(TM)(anastrozole) plus Herceptin (trastuzumab) is a better treatment option than hormonal therapy alone, for women with a certain ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that the Company received approval from the German Competent Authority to conduct a pivotal Phase III clinical trial for the treatment of moderate to severe psoriasis with its lead immunosuppressive drug, ISA247. The Phase III ...
NEW- YORK, September 29 (ots/PRNewswire) - Sanofi Pasteur, the vaccines business of sanofi-aventis, and the Pediatric Dengue Vaccine Initiative (PDVI) announced today their partnership to help develop and make a Dengue vaccine widely available for the global prevention of Dengue fever, the second most widespread tropical disease after malaria. Dengue fever ...
Istanbul, Turkey (ots/PRNewswire) - PharmaMar, the biopharmaceutical company specialising in cancer therapy, announces today that it is to present new data from two of its clinical compounds, Kahalalide F and Aplidin(R), at the 31st European Society for Medical Oncology Congress (ESMO) being held in Istanbul, Turkey from 29 September to 3 October 2006. Data will ...
Alderley Park, England (ots/PRNewswire) - - First Patient Enrolled in Pivotal International Randomised, Double-Blind Study of Vandetanib Versus Erlotinib FOR NON-US HEALTHCARE PROFESSIONAL PRESS ONLY AstraZeneca (NYSE:AZN) today announced the start of enrolment into a new Phase III study of the novel ...
Cordis Medizinische Apparate GmbH
Paris (ots/PRNewswire) - - Shipment of First Third-Generation Drug-eluting Stent Starts Cordis Corporation, the world leader in the drug-eluting stent market, announced today the launch of the CYPHER SELECT(TM) Plus Stent. The first third-generation drug-eluting stent is now available to physicians and patients in many markets around the world, including countries in Western and Eastern Europe, Asia Pacific ...
SWIFTWATER, Pennsylvania & LYON, France, September 26 (ots/PRNewswire) - - Flu Vaccine Based on New Technology Within U.S. Government Preparedness Program Sanofi pasteur, the vaccines business of the sanofi-aventis Group (NYSE: SNY), initiated its first clinical study today with a new generation of seasonal influenza vaccine produced using cell ...
Toronto, Canada (ots/PRNewswire) - Medify Solutions Limited (Pink Sheets - MDFY), today announced that it has signed an agreement with AlwaysON, a leading provider of managed IP communications services. This contract will provide the underpinning network infrastructure and telecommunication services for the rollout and delivery of the MedifyRemote application to ...
Lyon, France (ots/PRNewswire) - Sanofi pasteur, the vaccines business of the sanofi-aventis Group, has within the framework of FLUPAN, a collaborative research project funded by the European Commission, generated the first clinical trial lot of a new generation of H7N1 pandemic vaccine. This trial will broaden ...
World Federation for Mental Health
Paris (ots/PRNewswire) - - Multi-National Survey Highlights Gaps in PCPs Knowledge About Depression and Painful Physical Symptoms Nine of 10 young primary care physicians (PCPs) believe medical school training about depression -- specifically regarding its painful physical symptoms -- needs to be improved, according to findings from a multi-national survey ...
New York (ots/PRNewswire) - - Lyrica's neuropathic pain indication broadened to include central nerve pain; Central nerve pain is associated with conditions such as spinal cord injury, stroke, and multiple sclerosis - A robust and unprecedented clinical program involving more than 10,000 patients supports Lyrica's efficacy and safety in ...
Paris (ots/PRNewswire) - - For Healthcare and Medical Reporters (non-US) Bipolar disorder is the sixth largest cause of disability worldwide in people aged 15-44 years[1] and is commonly mistaken for other diseases such as acute depression. Consequently, people may suffer with symptoms for years before receiving appropriate treatment and up to half of all ...
Natick, Massachusetts (ots/PRNewswire) - Boston Scientific Corporation (NYSE: BSX) today welcomed the results of two studies and an editorial published in today's edition of The New England Journal of Medicine (NEJM), all of which reaffirmed the safety and efficacy of drug-eluting stents. Commenting on the ...
The Bill & Melinda Gates Foundation
Seattle (ots/PRNewswire) - - Four Grants Support Development of Vaccines and Better Drugs, and Launch of New Medical Journal The Bill & Melinda Gates Foundation today announced four grants totaling US$68.2 million to help accelerate research on neglected tropical diseases, including hookworm, leishmaniasis, and trypanosomiasis, which kill or disable ...
Copenhagen, Denmark (ots/PRNewswire) - Eli Lilly and Company (NYSE: LLY), Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), and Alkermes, Inc. (Nasdaq: ALKS) today announced detailed results from a safety and efficacy study of the long-acting release (LAR) formulation of exenatide. Data from the study demonstrated ...